A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
Public ClinicalTrials.gov record NCT05729568. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Randomized, Open-label Study to Evaluate the Safety and Efficacy of Broadly Neutralizing Antibodies (bNAbs) GS-5423 and GS-2872 in Combination With the Capsid Inhibitor Lenacapavir as Long-Acting Treatment Dosed Every 6 Months in Virologically Suppressed Adults With HIV-1 Infection
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this study is to test the effectiveness, safety, and tolerability of the combination of broadly neutralizing antibodies (bNAbs) (teropavimab (TAB; GS-5423) and zinlirvimab (ZAB; GS-2872)) with lenacapavir (LEN) in virologically suppressed adults with HIV-1 infection. The purpose of this study is to evaluate the efficacy of switching to a regimen of LEN, TAB and ZAB, versus continuing on baseline oral antiretroviral therapy (ART) as determined by the proportion of participants with human immunodeficiency virus-1 (HIV-1) ribonucleic acid (RNA) ≥ 50 copies/mL at Week 26.
Study identification
- NCT ID
- NCT05729568
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 83 participants
Conditions and interventions
Conditions
Interventions
- Teropavimab Drug
- Zinlirvimab Drug
- Lenacapavir Tablet Drug
- Lenacapavir Injection Drug
- Antiretroviral Therapy Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 15, 2023 (Actual)
- Primary completion
- Jul 2, 2024 (Actual)
- Completion
- Dec 2030 (Estimated)
- Last update posted
- Apr 27, 2026
2023 – 2030
United States locations
- U.S. sites
- 29
- U.S. states
- 14
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ruane Clinical Research Group, Inc. | Los Angeles | California | 90036 | — |
| Mills Clinical Research | Los Angeles | California | 90069 | — |
| UC San Diego (UCSD) AntiViral Research Center (AVRC) | San Diego | California | 92103 | — |
| Optimus Medical Group | San Francisco | California | 94102 | — |
| University of Colorado Clinical and Translational Research Center | Aurora | Colorado | 80045 | — |
| Yale University; School of Medicine; AIDS Program | New Haven | Connecticut | 06510 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| Midland Florida Clinical Research Center, LLC | DeLand | Florida | 32720 | — |
| Can Community Health Care | Fort Lauderdale | Florida | 33316 | — |
| Midway Immunology and Research Center | Ft. Pierce | Florida | 34982 | — |
| Orlando Immunology Center | Orlando | Florida | 32803 | — |
| Triple O Research Institute, P.A. | West Palm Beach | Florida | 33407 | — |
| Emory University Hospital Midtown Infectious Disease Clinic | Atlanta | Georgia | 30308 | — |
| Infectious Disease Specialists of Atlanta | Decatur | Georgia | 30033 | — |
| Southhampton Healthcare, Inc | St Louis | Missouri | 63139 | — |
| AXCES Research Group, LLC | Albuquerque | New Mexico | 87109 | — |
| Montefiore Medical Center | The Bronx | New York | 10467 | — |
| NC TraCS Institute - CTRC; University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27514 | — |
| Duke University Health Center | Durham | North Carolina | 27710 | — |
| Regional Center for Infectious Disease Research | Greensboro | North Carolina | 27401 | — |
| The Brody School of Medicine at East Carolina University | Greenville | North Carolina | 27858 | — |
| Rosedale Health and Wellness | Huntersville | North Carolina | 28078 | — |
| Prisma Health - Clinical Research Unit | Columbia | South Carolina | 29203 | — |
| St Jude Children's Research Hospital | Memphis | Tennessee | 38105 | — |
| Central Texas Clinical Research | Austin | Texas | 78705 | — |
| AIDS Arms, Inc. DBA Prism Health North Texas | Dallas | Texas | 75208 | — |
| AXCES Research Group, LLC | El Paso | Texas | 79902 | — |
| The Crofoot Research Center, INC | Houston | Texas | 77098 | — |
| Clinical Alliance for Research & Education, Infectious Diseases LLC (CARE-ID) | Annandale | Virginia | 22003 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05729568, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 27, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05729568 live on ClinicalTrials.gov.